Profile data is unavailable for this security.
About the company
Navamedic ASA is a Norway-based pharmaceutical company. It is a supplier of products delivered to hospitals and pharmacies. Navamedic’s product portfolio consists of prescription and Over The Counter (OTC) pharmaceuticals as well as other healthcare products registered as medical nutrition, medical devices, food supplements or cosmetics. The Company’s offering is divided into four product areas: Consumer Health, Specialty Pharma, Medical Nutrition and Branded Generics. The Company has one business segment which is the Pharma division. Navamedic ASA is present in all Nordic countries, the Baltics and Benelux. The Company has two subsidiaries, Navamedic AB, through which the Company distributes more than 40 products and a Norway-based Novicus Pharma AS.
- Revenue in NOK (TTM)512.00m
- Net income in NOK3.81m
- Incorporated2002
- Employees10.00
- LocationNavamedic ASAHenrik Ibsensgate 90OSLO 0255NorwayNOR
- Phone+47 67112540
- Fax+47 67112541
- Websitehttps://navamedic.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| COSMO BIO COMPANY, LIMITED | 668.23m | 31.62m | 435.73m | 155.00 | 13.26 | 0.6958 | 9.98 | 0.6521 | 75.93 | 75.93 | 1,602.48 | 1,447.21 | 0.8818 | 5.61 | 3.38 | 60,258,060.00 | 4.36 | 5.62 | 5.17 | 6.72 | 34.80 | 37.40 | 4.95 | 6.23 | 5.40 | -- | 0.0022 | 33.53 | -2.23 | 5.16 | -14.51 | 11.20 | -8.03 | 16.47 |
| Rekah Pharmaceutical Industry Ltd | 950.66m | -20.42m | 458.77m | 434.00 | -- | 0.9963 | 6.75 | 0.4826 | -0.6267 | -0.6267 | 29.37 | 13.52 | 0.6894 | 2.56 | 2.56 | -- | -1.48 | 0.543 | -2.13 | 0.7364 | 24.93 | 26.41 | -2.15 | 0.8367 | 1.08 | 0.2954 | 0.5414 | -- | 10.01 | 10.13 | -238.56 | -- | -4.89 | -- |
| Kingworld Medicines Group Ltd | 1.64bn | 57.91m | 464.19m | 1.00k | 7.61 | 0.4933 | 3.74 | 0.2831 | 0.0696 | 0.0696 | 1.97 | 1.07 | 0.8294 | 7.89 | 13.47 | 1,163,161.00 | 4.74 | 4.07 | 8.57 | 8.00 | 26.02 | 29.72 | 5.71 | 5.59 | 1.02 | -- | 0.3363 | 41.83 | 12.63 | -0.0034 | 67.52 | -1.46 | 54.82 | 9.24 |
| McPherson's Ltd | 1.46bn | -25.71m | 508.94m | 876.00 | -- | 0.6444 | 30.19 | 0.3497 | -0.0248 | -0.0248 | 1.40 | 0.7604 | 0.9907 | 2.09 | 5.72 | -- | -1.75 | 1.04 | -2.56 | 1.50 | 50.15 | 46.06 | -1.77 | 0.9152 | 0.9103 | 2.82 | 0.1822 | 409.37 | -1.79 | -0.0665 | -1,619.82 | -- | 0.3719 | -18.80 |
| Navamedic ASA | 512.00m | 3.81m | 585.74m | 10.00 | 153.65 | 2.62 | 37.22 | 1.14 | 0.2187 | 0.2187 | 29.61 | 12.84 | 1.13 | 3.39 | 6.24 | -- | 0.8409 | 0.0724 | 1.29 | 0.1177 | 38.88 | 38.33 | 0.7449 | 0.0704 | 0.5558 | 1.85 | 0.4069 | -- | 33.98 | 22.72 | -87.04 | 0.3123 | 59.60 | -- |
| Kim Forest Enterprise Co Ltd | 140.90m | -34.79m | 670.95m | -- | -- | 3.33 | -- | 4.76 | -2.22 | -2.22 | 9.01 | 11.80 | 0.4568 | 3.35 | 3.30 | -- | -11.28 | -0.8245 | -14.85 | -1.06 | 18.94 | 31.99 | -24.69 | -1.25 | 1.26 | -796.41 | 0.2673 | -- | -38.11 | 12.36 | -341.58 | -- | -8.51 | -- |
| Sinco Pharmaceuticals Holdings Ltd | 3.86bn | 64.38m | 680.73m | 278.00 | 10.57 | 0.713 | 7.66 | 0.1763 | 0.0225 | 0.0225 | 1.35 | 0.3338 | 1.53 | 22.60 | 5.73 | 9,872,404.00 | 2.56 | 6.48 | 6.55 | 20.22 | 12.73 | 14.79 | 1.67 | 3.86 | 1.08 | 28.20 | 0.2859 | 7.21 | 11.82 | 21.66 | -39.03 | -- | 123.63 | -- |
| Hyphens Pharma International Ltd | 1.38bn | 69.53m | 690.03m | 440.00 | 9.93 | 1.35 | 7.47 | 0.4984 | 0.0277 | 0.0277 | 0.5513 | 0.2037 | 1.45 | 4.65 | 4.89 | 387,715.90 | 7.29 | 8.35 | 12.10 | 14.01 | 36.29 | 37.06 | 5.03 | 5.65 | 1.35 | -- | 0.0939 | 33.00 | 5.10 | 7.12 | -24.52 | 9.63 | -18.70 | 9.35 |
| Able View Global Inc | 1.83bn | 101.76m | 699.73m | 117.00 | 6.95 | 8.06 | 6.76 | 0.3832 | 0.2186 | 0.2186 | 3.92 | 0.2654 | 3.10 | 7.17 | 10.56 | 1,612,720.00 | 17.99 | -- | 31.58 | -- | 22.81 | -- | 5.81 | -- | 2.13 | 6.94 | 0.4676 | -- | 23.81 | -- | -12.06 | -- | -- | -- |
Data as of May 02 2024. Currency figures normalised to Navamedic ASA's reporting currency: Norwegian Krone NOK
19.77%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Nordea Investment Management ABas of 31 Dec 2023 | 1.59m | 9.16% |
| Fondita Fund Management Co. Ltd.as of 31 Mar 2024 | 650.00k | 3.75% |
| Aktia Fondbolag Abas of 28 Mar 2024 | 400.00k | 2.31% |
| Handelsbanken Fonder ABas of 31 Mar 2024 | 305.15k | 1.76% |
| First Fondene ASas of 10 Feb 2023 | 245.00k | 1.41% |
| Schroder Investment Management Ltd.as of 30 Jun 2023 | 240.00k | 1.38% |
More ▼
Data from 30 Jun 2023 - 31 Mar 2024Source: FactSet Research Systems Inc.
